In a significant development for the Indian healthcare sector, Sun Pharmaceutical Industries Limited and Bayer have announced a collaborative agreement to market and distribute a second brand of Finerenone in India. This move is set to revolutionize the treatment landscape for chronic kidney disease (CKD) associated with type 2 diabetes mellitus (T2DM). Finerenone: A Game-Changer […]
Sun Pharmaceutical Industries Limited has entered into a license agreement with U.S.-based biopharmaceutical company Pharmazz Inc. for the commercialization of the first-in-class innovative drug, Tyvalzi (Sovateltide), in India. The deal terms include undisclosed upfront and milestone payments, as well as royalties to Pharmazz. Sovateltide is indicated for treating cerebral ischemic stroke and has recently been […]
Sun Pharmaceutical Industries (Sun Pharma) said that one of its fully-owned subsidiaries has launched the generic version of Pfizer-developed Palbociclib in India for patients with advanced breast cancer. The Indian pharma company will make the anti-cancer drug available under the brand name PALENO (Palbociclib) 75 mg, 100 mg, and 125 mg. Palbociclib has approval in […]
Sun Pharmaceutical Industries (Sun Pharma) said that it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for expanding access to the latter’s baricitinib in India. The Indian pharma company Sun Pharma will manufacture and distribute baricitinib in India. Baricitinib has been granted restricted emergency use by India’s Central Drugs Standard […]